Drugs.com - New Drug Approvals

FDA Approves Novartis Radioligand Therapy Pluvicto for Earlier Use Before Chemotherapy in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Basel, March 28, 2025 – Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic...

Mar 29, 2025 - 02:27
 0
FDA Approves Novartis Radioligand Therapy Pluvicto for Earlier Use Before Chemotherapy in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Basel, March 28, 2025 – Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic...
Read More

Tags:

Previous Article

An Electrochemically Paralleled Biomass Electrolyte Additive Facilitates the Int...

Next Article

New Long-Duration Energy Storage System To Challenge Tesla Megapack

Related Posts

FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair

FDA Approves Omlyclo (omalizumab-igec), an Interchangea...

Mar 7, 2025  0

FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves Vtama (tapinarof) Cream for the Treatment ...

Feb 9, 2025  0

FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer

FDA Grants Accelerated Approval to Bizengri (zenocutuzu...

Feb 9, 2025  0